PT  - JOURNAL ARTICLE
AU  - Paschalina Kontou
AU  - Kalliopi Chatzika
AU  - Katerina Manika
AU  - Georgia Pitsiou
AU  - Maria Sionidou
AU  - Ioannis Kioumis
TI  - Pharmacokinetics and pharmacodynamics of newer fluoroquinolones in patients with lower respiratory tract infections
DP  - 2012 Sep 01
TA  - European Respiratory Journal
PG  - P2454
VI  - 40
IP  - Suppl 56
4099  - http://erj.ersjournals.com/content/40/Suppl_56/P2454.short
4100  - http://erj.ersjournals.com/content/40/Suppl_56/P2454.full
SO  - Eur Respir J2012 Sep 01; 40
AB  - Introduction: Levofloxacin (LVF) and moxifloxacin (MXF), have been recommended as first line therapy for patients with acute exacerbations of chronic bronchitis and community-acquired pneumonia.Aim: The aim of this study is to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) parameters of LVF and MXF for lower respiratory tract infections (LRTI).Methods: Eighteen patients (2 groups of 9, aged 69.6±8.7 and 74±8.8) with LTRI received 500 mg LVF IV q12h or 400 mg MXF IV q24h. Serial blood samples were obtained at steady state condition (3rd day of therapy). Plasma concentrations were determined by a validated HPLC method. The PD target was evaluated for both antibiotics based on our hospital's MIC90 of the most common respiratory pathogens.Results: The PK data are presented in Table 1.View this table:Table 1.Both antibiotics exhibited large volumes of distribution (Vss). They achieved the PD target in all patients against the majority of strains of the commonest respiratory pathogens in our hospital, as shown in table 2.View this table:Table 2Conclusions: LVF and MXF exhibit a favorable PK profile in patients with LRTI. There is adequate PD exposure against most strains of S. pneumoniae, H. influenzae and M. catarrhalis with low MICs.